0GT Stock Overview
An early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
Stoke Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$8.85 |
| 52 Week High | US$16.10 |
| 52 Week Low | US$3.76 |
| Beta | 0.95 |
| 1 Month Change | -28.63% |
| 3 Month Change | -17.29% |
| 1 Year Change | 85.92% |
| 3 Year Change | -47.63% |
| 5 Year Change | -58.64% |
| Change since IPO | -63.46% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0GT | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -15.7% | 5.8% | 2.0% |
| 1Y | 85.9% | -6.1% | 9.6% |
Return vs Industry: 0GT exceeded the German Biotechs industry which returned -6.1% over the past year.
Return vs Market: 0GT exceeded the German Market which returned 9.6% over the past year.
Price Volatility
| 0GT volatility | |
|---|---|
| 0GT Average Weekly Movement | 9.2% |
| Biotechs Industry Average Movement | 7.4% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.7% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 0GT's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 0GT's weekly volatility has decreased from 15% to 9% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 110 | Ed Kaye | www.stoketherapeutics.com |
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy.
Stoke Therapeutics, Inc. Fundamentals Summary
| 0GT fundamental statistics | |
|---|---|
| Market cap | €478.03m |
| Earnings (TTM) | -€102.23m |
| Revenue (TTM) | €16.23m |
28.3x
P/S Ratio-4.5x
P/E RatioIs 0GT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0GT income statement (TTM) | |
|---|---|
| Revenue | US$16.74m |
| Cost of Revenue | US$0 |
| Gross Profit | US$16.74m |
| Other Expenses | US$122.20m |
| Earnings | -US$105.46m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.99 |
| Gross Margin | 100.00% |
| Net Profit Margin | -629.86% |
| Debt/Equity Ratio | 0% |
How did 0GT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/08 00:25 |
| End of Day Share Price | 2025/01/08 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Stoke Therapeutics, Inc. is covered by 17 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Gregory Harrison | BofA Global Research |
| Thomas Shrader | BTIG |
| Michelle Gilson | Canaccord Genuity |